Background: Enamel matrix derivative (EMD) was shown to enhance soft tissue healing and regeneration of the periodontium; however, the mechanisms of this action are unknown. It is assumed that amelogenin, the most abundant protein in EMD, is the protein primarily responsible for the effects of EMD. The purpose of this study was to fractionate EMD and associate its specific cellular effects with different molecular weight fractions following size-exclusion chromatography.
P eriodontal regeneration has been approached in many ways with varying degrees of success and predictability. The lack of predictability may result from a requirement for the integration of cellular and molecular effects to achieve regeneration of each tissue component: the alveolar bone, periodontal ligament (PDL), and cementum that together form the periodontal attachment apparatus. Because of the complexity of the interactions of the many cell types, growth factors, and other proteins associated with periodontal regeneration, there are conflicting results from research about how these elements function individually and in concert to regenerate a diseased periodontium. A current approach to regenerative therapy includes the use of a complex mixture of proteins that is purified from enamel matrix and is referred to as enamel matrix derivative (EMD). Initial clinical observations suggest that EMD is an effective therapeutic agent for periodontal regeneration. [1] [2] [3] [4] [5] [6] The mechanisms underlying the positive effects of EMD on the regenerative process remain largely unknown. An in vitro study 7 has shown that EMD has diverse effects on a variety of cell types, including PDL cells, osteoblasts, and vascular cells. Depending on the cell type, EMD stimulates proliferation, differentiation, or both. EMD enhances the attachment and spread of PDL cells, as well as the release of transforming growth factor-beta 8 and vascular endothelial growth factor (VEGF). 9 The material may also inhibit the growth of Gram-negative periodontal pathogens. 10 Investigators have proposed that the cellular effects associated with EMD are due primarily to the protein amelogenin, which is the predominant component of EMD and makes up ;90% of the material. One study 11 reported that the proliferative activity observed when cells were exposed to EMD was not due to amelogenin but to some other component in the protein mixture. Analysis of gene-expression profiles of PDL cells treated with EMD demonstrated that inflammatory genes were downregulated, whereas other genes coding for growth factors and their receptors were upregulated. 12 By contrast, other reports confirm that amelogenin contains integrin-binding sites required for cellular attachment 13, 14 and that the protein promotes cell attachment and spreading. 15 A controversial suggestion is that amelogenin has the capacity to stimulate immature mesenchymal cells to change their phenotype and enter tissue-specific maturation pathways. 16, 17 By contrast, other studies suggest that bone morphogenetic proteins (BMPs) 18, 19 or transforming growth factors 20 are responsible for the effects of EMD on cell differentiation. Thus, the extent to which the observed beneficial effects of EMD on periodontal regeneration result from the action of amelogenin remains to be resolved. Therefore, the goal of this study was to fractionate the various proteins contained in EMD to characterize their effects on differentiation, proliferation, angiogenesis, and collagenolytic activities.
MATERIALS AND METHODS
Multiple 30-mg vials of unheated, lyophilized EMD ‡ from the same lot number were used in this study. This material was not heat-treated and, therefore, it differs from the material that is available commercially. A fresh stock solution was prepared by dissolving EMD in 10 mM acetic acid and allowing it to stand at 4°C for ‡1 hour prior to using it to solubilize the material. Control solutions were prepared similarly from 10 mM acetic acid vehicle. For column separations, EMD was dissolved in 0.05 M sodium bicarbonate buffer, pH 10.8. Freshly dissolved material was allowed to stand at 4°C for ‡1 hour prior to column application to solubilize the material. It has been shown that although enamel matrix proteins tend to aggregate and become insoluble at physiologic pH and temperature, the solubility increases at acid or alkaline pH and low temperature. 21, 22 Porcine amelogenin, prepared as described by Ryu et al., 23 was the generous gift of Dr. James Simmer, University of Michigan School of Dentistry, Ann Arbor, Michigan. Working solutions of amelogenin for cell culture studies were prepared by diluting a stock solution of 15 mg/ml in 10 mM acetic acid with cell culture media appropriate for the experiment and cell type studied.
C2C12 cells (CRL-1772) served as an in vitro model cell system for evaluating the differentiation potential of EMD on osteoprogenitor cells. § The C2C12 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 4 mM L-glutamine and adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 10% fetal bovine serum (FBS).
Human microvascular endothelial cells (HMVECs) served as a model vascular cell. i Three lot numbers derived from dermal neonatal tissue and pooled from multiple donors were used over the course of the project: 3F1066, 3F1489, and 4F1613. The cells were maintained in endothelial cell growth medium 2 microvascular (EGM2 MV) medium. This medium was prepared from endothelial cell basal medium 2 (EBM2) medium ¶ by adding components of a growth factor supplement kit. # Cells were used as long as they maintained the same endothelial cell morphology evident in the parent culture but usually for no more than four or five passages.
EMD Fractionation
EMD was fractionated at 4°C using a 2.5 · 100-cm column of cross-linked dextran particle matrix,** equilibrated with 0.05 M sodium bicarbonate buffer, pH 10.8 (column buffer). The column flow rate was 21 ml/hour. The elution profile of the column and a molecular weight calibration curve were determined prior to EMD fractionation. EMD (30 mg) dissolved in 5 ml column buffer was applied to the column, and the eluate was collected in 20-minute (7 ml) fractions. Aliquots from each fraction were assayed for protein content using the BCA protein assay. † † The protein-elution pattern was determined by plotting the protein content of each fraction aliquot versus the fraction number. Fractions were desalted over protein desalting (10,000 MW) columns, ‡ ‡ lyophilized, and the protein concentration was confirmed after resuspension in 10 mM acetic acid. Samples were stored at -20°C. At the time of assay, the protein concentration of each fraction was adjusted to 50 mg/ml using DMEM cell culture medium. Some fractions did not contain detectable protein and were not tested.
Determination of Alkaline Phosphatase Activity C2C12 cells were plated into 96-well plates at 2 · 10 4 cells/well in DMEM containing 4 mM L-glutamine and adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 10% FBS (growth medium). After 18 hours, the medium was removed and replaced with fresh growth medium containing 5% FBS and EMD or amelogenin at concentrations of 0, 6.25, 12.5, 25, 50, or 100 mg/ml. Fractionated EMD samples were tested at a final protein concentration of 25 mg/ml. Fractionated EMD samples were also preincubated with 100 ng/ml noggin § § for 1 hour prior to addition to the cells. At the appropriate time (0, 2, 5, or 9 days), the medium was removed, and the cell layer was washed twice with phosphate buffered saline (PBS). To measure alkaline phosphatase activity, 50 ml PBS and 50 ml 1:1:1 (volume [vol] :vol:vol) mixture of 1.5 M 2-amino2-methyl-1-propanol, pH 10.25, 20 mM pnitro-phenyl phosphate, and 10 mM MgCl 2 were added to each well and incubated with the cells for 40 minutes at 37°C. The reaction was stopped by the addition of 100 ml 1 N sodium hydroxide, and the absorbance was read at 405 nm. A standard curve was prepared from known concentrations of p-nitrophenol (PNP). The alkaline phosphatase activity was expressed as the amount of PNP formed/well/40 minutes.
Analysis of Cell Proliferation
HMVECs (5 · 10 3 cells/well) were plated into 96-well plates in 200 ml EGM2 MV medium. After 18 hours, the medium was removed and replaced with EBM2 medium containing 2% serum and EMD or amelogenin at concentrations of 0, 6.25, 12.5, 25, 50, or 100 mg/ml. Fractionated EMD samples were tested at a final protein concentration of 25 mg/ml. After incubation for 72 hours at 37°C (5% CO 2 : 95% air), the medium was removed and replaced with fresh serum-free culture medium containing 10% (vol:vol) water-soluble tetrazolium 1 reagent. ii Incubation was continued for 2 hours at 37°C prior to determining the absorbance of the reaction products at 450 nm.
In Vitro Angiogenesis Assay A 96-well angiogenesis system ¶ ¶ was used to determine the angiogenic activity of EMD, amelogenin, and fractionated EMD samples in vitro. Twenty thousand HMVECs in 50 ml EBM2 medium containing 5% serum but no endothelial cell growth factors (control -) were plated per well. An additional 50 ml medium containing EMD or amelogenin at 50 mg/ml or EMD fractions containing 50 mg protein/ml was added to each well. Control wells contained the same number of cells in EBM2 medium containing 5% serum and the endothelial cell growth factors (control +). The plates were incubated at 37°C in humidified air containing 5% CO 2 and 95% air. At time periods from 0 to 4 hours, the plates were removed from the incubator, and digital images were obtained using brightfield microscopy at ·100. The images were scored masked for the extent of angiogenesis using a previously defined (0 to 5) scoring system ## based on that reported by Malinda et al. 24 Polyacrylamide Gel Electrophoresis EMD and amelogenin were resolved on 15% polyacrylamide gels using the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) procedure described by Laemmli. 25 Aliquots of 5 or 2.5 mg unfractionated EMD or amelogenin or 2 mg fractionated EMD were applied to the gel. Resolved bands were stained with Coomassie brilliant blue R-250 and photographed. For determination of enzyme activity, the gels were copolymerized with 150 mg/ml denatured type I collagen as described by Overall and Limeback 26 and modified by Steffensen et al. 27 Data Analysis Data were analyzed by analysis of variance with the Tukey method as the post hoc test using statistical software.*** Angiogenesis scoring was analyzed using the Kruskal-Wallis test.
RESULTS
Baseline activities for unfractionated EMD and purified amelogenin were determined for C2C12 and HMVEC lines before separating EMD into fractions for testing.
Alkaline Phosphatase Activity Differentiation of C2C12 was evaluated on days 2, 5, and 9 by determining alkaline phosphatase activity following stimulation by EMD or amelogenin at concentrations between 0 and 100 mg/ml. On day 2, there was no increase in alkaline phosphatase activity for any of the EMD concentrations tested compared to the unstimulated control (data not shown). On day 5, the increase in alkaline phosphatase activity was statistically significant at each concentration of EMD tested compared to unstimulated control cells (Fig.  1A) . The increase in alkaline phosphatase activity on day 9 was not significant because of an increase in the baseline activity of the unstimulated control cells (data not shown). These results are consistent with those reported by Ohyama et al., 28 who reported that EMD-stimulated alkaline phosphatase activity of C2C12 cells was maximal on day 7 and that baseline activity gradually increased during culture in the absence of EMD. Thus, the results showed that EMD stimulated C2C12 cell differentiation in a time-and dose-dependent manner. By contrast, there were no significant increases in alkaline phosphatase activity at any of the amelogenin concentrations tested on days 2, 5, or 9, indicating that differentiation did not occur in response to stimulation by this factor (data not shown).
Proliferation Activity
When stimulated with EMD or amelogenin in 2% serumcontaining medium, HMVEC proliferation was significantly increased at all concentrations tested compared to the 2% serum control. The greatest increase in EMDstimulated HMVEC proliferation occurred at 25 mg/ml (P <0.001; Fig. 1B) . Although proliferation was increased compared to the unstimulated control at EMD concentrations of 50 and 100 ml/ml, the magnitude of the increase was significantly less than the peak stimulation at 25 ml/ml (P <0.01). By contrast, amelogenin-stimulated proliferation peaked at 6.25 mg/ml (P <0.001), the lowest concentration of amelogenin tested (Fig. 1C) . Amelogenin concentrations ranging from 12.5 to 100 mg/ml stimulated proliferation to levels that were not significantly different from that seen following stimulation with 6.25 mg/ml of the factor.
Angiogenesis
At 4 hours following stimulation by 25 mg/ml EMD, there was a significant increase (P <0.015) in the angiogenesis score to 2.5 compared to the unstimulated control, indicating that capillary-like tubes were now A) Effect of EMD on alkaline phosphatase activity of C2C12 cells. At day 5, there was a statistically significant increase for each concentration of EMD tested compared to unstimulated control. B) Effect of EMD on HMVEC proliferation. EMD in medium containing 2% serum stimulated significant increases in HMVEC proliferation at all concentrations tested compared to the 2% serum control. The greatest increase in EMD-stimulated HMVEC proliferation occurred at 25 mg/ml. C) Effect of amelogenin on HMVEC proliferation. When stimulated with amelogenin in medium containing 2% serum, proliferation was significantly increased at all concentrations tested compared to the 2% serum control. For any concentration tested, amelogenin-stimulated proliferation was not significantly different from 6.25 mg/ml, the lowest concentration of amelogenin tested. D) Effect of EMD and amelogenin (AMEL) on HMVEC angiogenesis after 4 hours. At 4 hours following stimulation by EMD (25 mg/ml), there was a significant increase (P <0.015) in the angiogenesis score to 2.5, indicating that capillary tubes were now visible. Although not statistically significant, stimulation by EMD was greater than the stimulation by AMEL (25 mg/ml) and the positive control. By contrast, the effect of AMEL on angiogenesis at this time was not significantly different from the positive or negative control media. Data were analyzed by the Kruskal-Wallis test (n = 8). Data are mean -SEM (n = 8). *P <0.05; † P <0.001.
visible. The effect of 25 mg/ml amelogenin on angiogenesis at 4 hours was not significantly different from unstimulated control medium (Fig. 1D) .
SDS-PAGE Gel of EMD and Amelogenin
Unfractionated EMD proteins had a molecular weight <30 kDa, with the exception of one prominent band ;52 kDa. By contrast, the major band of the amelogenin preparation had a molecular weight of 29 kDa. Although there were a few weak bands with molecular weights >50 kDa, no protein bands were detected below 29 kDa (Fig. 2) .
EMD Protein Fractionation
During separation by gel filtration, the proteins in EMD separated into three distinct peaks as defined by the protein concentration in the eluate (Fig. 3A) . The first peak contained high molecular weight proteins ( ‡100 kDa) and was associated with the void volume. The second protein peak eluted at ;50 kDa, whereas proteins in the third peak were extrapolated from the standard curve to have molecular weights ;10 kDa.
Alkaline Phosphatase Activity of EMD Fractions
When the alkaline phosphatase activity of each fraction was determined at day 5 and superimposed on the EMD protein-separation profile (Fig. 3A) , it was evident that the strongest alkaline phosphatase activity occurred in fractions 12 through 17. These fractions did not correspond to any of the high-concentration protein peaks from EMD. In fact, there seemed to be little activity in the fractions containing the major EMD protein peaks. Subsequently, when fractions were preincubated with 100 ng/ml noggin, a decoy receptor known to bind to BMP-2, -4, and -7 and block their activity, the stimulation of alkaline phosphatase activity at day 5 was virtually eliminated in the fractions that had the highest effect prior to noggin treatment (Fig. 3B) , suggesting that the osteoinductive activity associated with EMD is not related to amelogenin but more likely to a member of the BMP family of proteins.
Stimulation of Proliferation by EMD Fractions
Unlike alkaline phosphatase activity, the stimulation of proliferative activity for HMVECs (Fig. 4) mirrored the EMD protein-separation profile, with the greatest proliferative activity occurring in the fractions coincident with the most abundant proteins.
Stimulation of Angiogenesis by EMD Fractions
An angiogenesis score of 4.0, signifying almost complete vascular maturity and organization, was achieved with proteins in the second peak of fractionated EMD. The early stages of angiogenesis, reflected by a score of 1 and indicating the beginning of cellular alignment, were observed in cells treated with the third protein peak. Finally, an angiogenesis score of 3.0, indicating sprouting from capillary-like tubes, was associated with the high molecular weight proteins in the void volume peak (Fig. 5) . The fractions between the void volume and the beginning of the second protein peak were not tested because protein was not detectable in these fractions from this column run.
Collagenolytic Activity of EMD Fractions
Enzyme activities on denatured type I collagen substrate gels were detected in the high molecular weight proteins eluted in peak 1 (Fig. 6, top) , as well as in proteins eluted in the molecular weight region of 50 to 70 kDa (Fig. 6, bottom) .
DISCUSSION
The results of this research demonstrate that EMD, which represents a complex mixture of proteins, has the ability to stimulate several activities in two cell types. Individual activities are associated with different molecular weight fractions of EMD separated by gel filtration. The data suggest that the single most abundant protein of EMD, amelogenin, may be associated with some, but not all, EMD properties. The results indicate that several of the activities stimulated by EMD are not stimulated by amelogenin present in EMD or the 29-kDa recombinant porcine amelogenin used in this study. Because no attempt was made to identify the proteins in the various fractions, the possibility remains that the observed effects resulted from high molecular weight aggregates of amelogenin or smaller molecular weight fragments. The proteins in EMD eluted in three distinct peaks from a cross-linked dextran particle matrix gel filtration column. The protein-separation profile was very similar to that reported by Iwata et al., 19 who purified and fractionated enamel matrix proteins obtained Proliferation activity of EMD fractions on HMVECs. Proliferation of HMVECs was determined and superimposed on the protein-separation profile for EMD. The proliferative activity for HMVECs mirrored the EMD protein-separation profile, with the greatest proliferative activity occurring in the fractions coincident with the major protein peaks, particularly the 10-kDa peak.
Figure 5.
Angiogenic activity of EMD fractions on HMVECs. Fractionated EMD was applied to HMVECs at a concentration of 25 mg/ml; angiogenesis was scored and plotted against the fraction number and then superimposed on the EMD protein-separation profile. Angiogenic activity at 4 hours was coincident with EMD protein peaks II and III. Note also that an angiogenesis score of 3.0 is associated with the void volume peak.
Figure 6.
Zymograms of EMD column fractions. Areas in which the collagen was degraded appear clear (unstained). Collagenolytic activity was evident in two areas, fractions 3 through 8 (top panel) and fractions 17 through 21 (bottom panel). Thus, the collagenolytic activity of EMD was associated with proteins eluting in peak I from the cross-linked dextran particle matrix column, as well as with proteins eluting in the 68-kDa molecular weight region, and well before the elution position of 28.9 kDa molecular weight amelogenin. No further collagenolytic activity was apparent in any of the later-eluting fractions (data not shown). ROS in lane 1 serves as a standard for collagenolytic activity and is an MMP-2-containing extract prepared from rat osteosarcoma cells. EMD in lane 2 is unfractionated EMD. Lanes 3 through 13 contain the protein eluted from the cross-linked dextran particle matrix column in fractions 1 through 11 (top panel) and fractions 12 through 22 (bottom panel).
from tooth germs of 6-month-old pigs and also found three distinct protein peaks using the same chromatography method. The presence of alkaline phosphatase and/or an increase in its activity is a common marker for cellular differentiation by osteoblasts and osteoprogenitor cells. Stimulation with EMD increased the alkaline phosphatase activity of C2C12 cells, a cell line commonly used to assay for osteoinductive activity, indicating that osteoblast differentiation occurred. These data are consistent with other articles 7, 28 indicating that EMD stimulates osteoblast cell differentiation and maturation. In the present study, when the capacity of individual fractions to induce alkaline phosphatase activity in C2C12 cells was superimposed on the EMD protein-separation profile, it became evident that this property of EMD did not correspond to any of the major peaks that reflected the abundance of protein in the fractions. Rather, the most prominent alkaline phosphatase activity was associated with molecular weight species that eluted between the first and second peaks. This pattern was also observed by Iwata et al., 19 who used the ST2 preosteoblast cell line. Furthermore, the present study found that preincubation of the column fractions with the BMP decoy receptor noggin prior to treating C2C12 cells inhibited the induction of alkaline phosphatase activity in the cells. This is consistent with results from the study by Iwata et al. 19 in ST2 cells, as well as those reported by Ohyama et al. 28 in C2C12 cells.
Finally, using C2C12 cells, which normally do not express core-binding factor a1/Runt-related transcription factor-2 (Cbfa1/Runx2) unless stimulated by BMP-2, 29 Takayama et al. 18 reported that EMD stimulated Cbfa1/Runx2 expression in the cells that was inhibited by noggin. Considered together, the data from the present study and the evidence from the literature are consistent with the concept that the osteoinductive activity associated with EMD cannot be attributed to amelogenin but is more likely derived from a member of the BMP family of proteins. This conclusion is based on the observation that the activity is inhibited by noggin 19 and is not observed in the molecular weight fractions expected to contain amelogenin or any of its fragments. This concept is strengthened by a report from Parkar and Tonetti, 12 in which gene arrays from PDL cells treated with EMD seemed to upregulate genes coding for growth factors and growth factor receptors while downregulating inflammatory genes. One of the specific genes upregulated is BMP-4, one of three BMPs known to be inhibited by noggin.
Vascular endothelial growth factor precursor was another of the genes reported to be upregulated by EMD in the study by Parkar and Tonetti. 12 Because new vessel formation is essential to wound healing, it follows that an upregulation of this growth factor may stimulate the necessary cellular activities in vascular cells that lead to improved wound healing. The results of the present study are consistent with this mechanism. For example, when HMVECs were stimulated with EMD, they showed a dose-dependent increase in proliferation over the concentration range of 0 to 25 mg/ml, whereas higher doses reduced the magnitude of the increase significantly below peak values. These results are consistent with similar results in HMVECs reported by Yuan et al. 30 in vitro and in a murine model. Results were similar when HMVECs were stimulated with amelogenin; doses >6.25 mg/ml did not produce any further increases in proliferation. A possible explanation for the fact that the higher doses of EMD and amelogenin resulted in decreased proliferation or the failure to produce further increases in proliferation is that these factors may stimulate HMVEC differentiation or apoptosis in a dose-dependent manner. In either case, the cells would be removed from the proliferating population. 9 Increases in proliferative activity that occurred in response to stimulation by column fractions corresponding to the second and third protein peaks suggest that the effect of EMD on HMVECs may be due, in part, to amelogenin. This suggestion is supported by the observation that HMVEC proliferation also was increased by treatment with recombinant porcine amelogenin. These data are also consistent with the suggestion that the proliferative activity for human microvascular endothelial cells is associated with molecular weight species of the EMD mixture that are distinct from those associated with the induction of alkaline phosphatase activity.
The effects of EMD on angiogenesis demonstrated in the present study are consistent with several reports in the literature. Yuan et al. 30 reported that EMD stimulated endothelial chemotaxis and angiogenesis. Schlueter et al. 9 suggested that EMD stimulates angiogenesis directly by stimulating endothelial cells and indirectly by stimulating the production of angiogenic factors, such as VEGF, by PDL cells. A study by Mirastschijski et al. 31 found that VEGF production by fibroblasts treated with EMD was increased compared to untreated control fibroblasts. The gene array studies by Parkar and Tonetti 12 also indicated that the expression of VEGF or its precursors was upregulated by EMD in PDL cells. The results of the present study also demonstrate that as was seen for proliferation, the capacity to stimulate angiogenesis corresponded to the major protein peaks, raising the possibility that this activity is associated with amelogenin or one of its fragments. Nevertheless, the fact that stimulation of HMVECs with recombinant porcine amelogenin did not stimulate angiogenesis in these cells suggests that the activity results from the effects of other proteins in the EMD mixture.
Proteolytic enzyme activities, or more specifically gelatinolytic activities, were detected in native EMD as well as in EMD fractionated by gel filtration. Activities consistent with MMP-2 according to the positive control sample from rat osteosarcoma (ROS) 17/2.8 cell-conditioned medium 32 were only very faintly detectable in the fractionated protein fractions. However, gelatinolytic activities with apparent masses of 40 and 45 kDa were readily detectable in fractions 3 through 8 and 17 through 21. These activities are consistent with enamelysin (MMP-20), which presents itself by this type of duplet appearance on gelatin zymograms. 33 Surprisingly, we found those activities in the highmass and, as expected, the medium-mass fractions. Because EMD was fractionated under native conditions, it is plausible that part of the putative MMP-20 activities were passing through the column bound to large carrier or substrate molecules and were not separated from those until the column fractions were separated by SDS-PAGE in preparation for the zymograms analysis. Very high molecular weight activities present in the zymograms could reflect such complexes that were not dissociated by the protein sample buffer. An analogy to this type of interaction is the binding in plasma of MMP-9 to neutrophil gelatinaseassociated lipocalin, which also is a feature of chronic and localized aggressive periodontitis. 34, 35 These results demonstrate that native EMD contains enzymes that are capable of degrading denatured type I collagen, an important aspect of tissue remodeling during wound healing and regeneration.
CONCLUSIONS
Although individual activities of EMD have been characterized and associated with specific proteincontaining regions of size exclusion columnfractionated EMD, individual activities likely do not occur exclusive of one another. Rather, the activities may act in concert with each other and the various cell types and/or receptors in a dynamic environment to stimulate and/or accelerate the regenerative process. It is likely that the effects of EMD are the result of multiple proteins present in the mixture and are not solely related to amelogenin.
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